It wasn’t a typical anatomy lab. The small group of people gathered around a table at Southwest Minnesota State University ...
Cipaglucosidase alfa/miglustat is an investigational therapy that is not yet approved by any regulatory agency. The posters will be made available on the Amicus website following their respective ...
ROCKVILLE, Md., Sept. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced Chief Medical Officer, Steve Pakola, M.D., will present at the ...
DURHAM, N.C., September 30, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo ...
BOSTON--(BUSINESS WIRE)-- PepGen Inc. (PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe ...
The presentation and posters will be available on the publications page of Avidity's website at https://www.aviditybiosciences.com. Sign up for our newsletter to get the latest on the transformative ...
-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy- -Company’s StealthX™ Technology Shows Promise of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback